‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
BioSpace

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Morningstar

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...

Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a late-stage trial for lung cancer. Read more here.
Hosted on MSN

Merck stock jumps as Keytruda combo trials boost cancer pipeline

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...
FiercePharma

Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
The New York Times

A New Shot for Cancer Is Convenient, but Poised to Keep Prices High

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...